GLP-1s & Medications

Adults using semaglutide as first obesity medication achieve greater weight loss, study finds

A recent study has indicated that adults commencing semaglutide as their initial treatment for obesity experience more substantial weight reduction compared to those who had previously used other obesity medications. This research, published in the journal Diabetes, Obesity and Metabolism, was conducted by Andres J. Acosta, MD, PhD, and his team at the Mayo Clinic in Rochester, Minnesota. It marks the first investigation into how prior use of anti-obesity drugs influences weight loss outcomes with semaglutide.

The retrospective cohort study analysed data from 305 adults treated at a Mayo Clinic centre from 2021 to January 15, 2023. Participants, who had an average age of 49 and were predominantly female (73%), received once-weekly subcutaneous injections of semaglutide (Wegovy, Novo Nordisk). The research team monitored body weight changes from baseline at 3, 6, 9, and 12 months after initiating treatment. Additionally, blood pressure and laboratory values were assessed at baseline and after one year.

Of those studied, 76% had not previously used any obesity medication before starting semaglutide, while 24% had used another obesity drug. Among the latter group, 28% had been treated with the GLP-1 receptor agonist liraglutide (Saxenda, Novo Nordisk), and 72% had used a non-GLP-1 obesity medication.

The findings revealed that those who were new to obesity medications and started with semaglutide saw a 14.3% reduction in body weight by 12 months, compared to a 10.6% decrease in those who had used other obesity treatments prior (P = .01). Despite similar proportions of both groups achieving at least 5% and 10% body weight loss, those new to obesity medication were significantly more likely to lose at least 15% (48% vs. 21%; P = .02) and at least 20% (27% vs. 4%; P < .01) of their body weight.

The analysis also showed a distinct pattern in weight loss during the first six months, where those without prior obesity medication use consistently lost more weight than those who had previously used liraglutide or other non-GLP-1 obesity drugs. By nine and twelve months, while weight loss among previous liraglutide users remained lower, those who had used other non-GLP-1 medications achieved similar weight loss to the semaglutide-naive group.

An interesting finding was that adults not previously on obesity medications exhibited a significant reduction in HbA1c levels at 12 months compared to their counterparts who had used such medications before (P < .001), although no other significant differences in metabolic outcomes were noted.

The study highlights a potential issue where prior usage of specific obesity treatments like liraglutide might lessen responsiveness to new medications such as semaglutide. The researchers suggested that these findings underscore the necessity for precision medicine in obesity management, advocating for treatment plans tailored to individual genetic backgrounds, environmental factors, and prior medication history to optimise effectiveness, reduce unnecessary drug exposure, and consider financial impacts on patients.

This study opens the door for further prospective research to explore and confirm the differential impacts of switching obesity medications and to enhance the understanding of optimal treatment strategies in obesity management.

Eli Lilly’s Tirzepatide shows up to 66% reduction in sleep apnea severity in adults with obesity

In a recent development, Eli Lilly & Co. announced that its weight-loss medication, Tirzepatide, has shown promising results in alleviating symptoms of obstructive sleep apnea, a disorder primarily associated with obesity. This revelation emerged from two advanced clinical trials, wherein Tirzepatide significantly reduced the incidences of diminished or halted breathing during sleep by up to 63%, surpassing the anticipations of Jefferies analysts who had projected a reduction range of 50% to 55%.

During these year-long studies, participants experienced a substantial decrease in body weight, with losses nearing 20%, as reported by Lilly. The pharmaceutical giant intends to present the comprehensive findings from these studies at the upcoming American Diabetes Association conference in June. Subsequently, plans are underway to submit these results to the U.S. Food and Drug Administration and other international regulatory bodies starting mid-year.

The potential approval of Tirzepatide for treating sleep apnea could significantly broaden patient access to the drug through insurance coverage. Currently, weight loss medications like Tirzepatide do not receive coverage under Medicare, the U.S. federal health programme for the elderly and certain individuals on long-term disability. Such approval would not only facilitate greater competition with Novo Nordisk A/S—whose leading weight-loss drug, Wegovy, has recently gained insurance coverage for some Medicare beneficiaries with cardiac conditions—but also position Lilly at the forefront of addressing the underlying causes of sleep apnea.

Jeff Emmick, Lilly’s senior vice president of product development, emphasised the transformative potential of Tirzepatide, highlighting its capacity as the inaugural pharmaceutical intervention targeting the fundamental aspects of the disease. Given the correlation between weight loss and improvements in sleep apnea symptoms, widespread insurance coverage for Tirzepatide could potentially prevent up to 5.6 million cases of this sleep disorder by 2030, as estimated by analytics firm Airfinity.

Nevertheless, despite these advances, analysts from Airfinity caution that while GLP-1 drugs like Tirzepatide will significantly reduce sleep apnea incidences, they are unlikely to eradicate the disorder entirely.

The study enrolled 469 participants suffering from obesity and sleep apnea, with some receiving Tirzepatide alone and others receiving both the drug and using breathing devices. Results indicated a more pronounced average reduction in the apnea-hypopnea index (AHI)—a diagnostic measure quantifying the severity of sleep apnea based on the number of breathing disruptions per hour of sleep—for those utilising both the medication and breathing devices compared to those solely on medication.

The approval of Tirzepatide for sleep apnea treatment could also influence the market for respiratory support devices. Companies like ResMed Inc. and Inspire Medical Systems Inc., which manufacture such equipment, may see a reduction in demand, with Airfinity projecting a potential market contraction of over 11% in the coming years due to the increased use of weight loss drugs as a therapeutic alternative.

European regulators find no evidence of link between new obesity medication and suicidal thoughts

Following an extensive nine-month investigation, European medical regulators have concluded that there is no evidence to suggest that GLP-1 receptor agonists, such as Ozempic and Wegovy, contribute to suicidal ideation or behaviours. This conclusion by the European Medicines Agency (EMA) aligns with a similar assessment conducted by the U.S. Food and Drug Administration (FDA) earlier in January, which also found no causal connection between these widely used medications for weight loss and diabetes and the risk of suicidal thoughts.

The investigation by the EMA began in July, 2023, after anecdotal instances were reported where patients exhibited self-harm thoughts while being treated with GLP-1 receptor agonists, specifically liraglutide (marketed as Saxenda by Novo Nordisk) and semaglutide (known commercially as Ozempic and Wegovy, also by Novo Nordisk). The concern prompted the EMA’s Pharmacovigilance Risk Assessment Committee to demand further information from the manufacturers of these medications in November.

Throughout the investigation, the committee meticulously analysed various sources including medical records, clinical trial data, post-marketing surveillance reports, and other academic studies. Notably, a study published in Nature Medicine indicated that the risk of suicidal ideation was actually lower in patients using GLP-1 drugs compared to those treated with other medications for obesity and diabetes. Ultimately, the EMA committee concluded that the evidence does not support a causal link between the use of GLP-1 receptor agonists and increased suicidal risk.

Despite these findings, the EMA has mandated continuous monitoring by manufacturers of GLP-1 based medications for any future incidents of suicidal thoughts or actions. This ongoing vigilance reflects a cautious approach, particularly given the historical context where earlier obesity treatments, such as rimonabant, were withdrawn from the European market in 2008 due to their association with increased suicidal ideation risks.

GLP-1 based treatments, including Ozempic, Wegovy, Eli Lilly’s Mounjaro, and Zepbound, have seen a surge in popularity recently. However, this increase in usage has coincided with sporadic anecdotal reports linking the drugs to suicidal thoughts, thus prompting these detailed investigations.

The FDA, in its preliminary review statement in January, mentioned that while a definitive exclusion of any risk is challenging, it is committed to further investigation to clarify this potential link. It is important to note that while the FDA’s approvals for Wegovy and Zepbound for obesity management include advisories for physicians to monitor for signs of suicidal thoughts, similar advisories are not included on the labels of Ozempic and Mounjaro, which are approved for managing type 2 diabetes.

This comprehensive review by regulatory bodies underscores a significant step in ensuring the safety and efficacy of GLP-1 medications, reaffirming their use in clinical practice amidst growing concerns over possible psychiatric side effects.

Weight-loss pharmaceuticals could spur 1% increase in US GDP, Goldman Sachs suggests

In a recent analysis, Goldman Sachs posits that the extensive deployment of innovative weight-loss medications across the United States has the potential to catalyse a significant uplift in the country’s Gross Domestic Product (GDP) by as much as 1% in the forthcoming years. This optimistic forecast is grounded in the anticipation that a reduction in obesity-related health issues could substantially enhance productivity within the workforce.

The market for these weight-loss medications is anticipated to burgeon, potentially reaching a staggering $100 billion annually by the decade’s end. Leading this burgeoning sector are pharmaceutical giants such as Novo Nordisk, the manufacturer of Ozempic, and Eli Lilly, the producer of Mounjaro. Both companies are at the forefront of developing a category of drugs known as GLP-1 agonists, which have garnered significant interest from various pharmaceutical firms. The projections by Goldman Sachs suggest that consumer uptake of GLP-1 agonists could surge, varying from 10 million to an ambitious 70 million by the year 2028.

The economists at Goldman Sachs elaborate on the potential economic ramifications of this increase in GLP-1 usage, linking it directly to anticipated declines in obesity rates. Citing academic research, they highlight the dual challenge posed by obesity: affected individuals are less likely to be employed and exhibit lower productivity levels when they are in the workforce. According to their analysis, an increase to 30 million users of weight-loss drugs could potentially boost the US GDP by 0.4%, with the potential for a 1% increase if user numbers reach 60 million.

However, the report has not been without its critics, especially from advocates of the body-positivity movement, who may view the report’s implications with scepticism or concern.

Moreover, the report underscores a broader wave of healthcare innovation, particularly highlighting the role of artificial intelligence (AI) in drug discovery processes, combined with the impact of GLP-1 agonists. Together, these advancements could elevate the US GDP by an additional 1.3%, translating to an economic boost of approximately $360 billion per annum at current exchange rates. The potential increase could range from 0.6% to 3.2%, with the effects expected to be more pronounced in the US compared to other developed nations, which generally exhibit better health outcomes.

In parallel, research into weight-loss drugs is expanding to explore their efficacy in treating a range of conditions, from alcohol dependency to dementia. Medications such as Ozempic and Wegovy, which contain the drug semaglutide, and another medication, liraglutide, used under various brand names for both diabetes and weight loss, have seen a surge in popularity. This is partly due to their proven capability to assist individuals in shedding more than 10% of their body weight. The potential for these drugs to confer additional health benefits is being actively investigated in new clinical trials, signalling a promising horizon for medical research and public health.

The delicate balance of preserving muscle mass in the age of weight loss pharmaceuticals

As the global population turns increasingly towards medications like Ozempic for weight loss solutions, a growing concern has emerged regarding the side effect of muscle loss associated with these treatments. This phenomenon has sparked a multifaceted response from various sectors aiming to mitigate this undesired outcome, thereby enhancing the overall health benefits of weight management efforts.

Luxury fitness centres are now tailoring strength-training regimes specifically for individuals utilising these medications, with the promise of maximising health results. These programmes are designed not just to counteract muscle degradation but to optimise the physical wellness journey of their clients. Concurrently, nutritional experts and bespoke meal delivery services are stepping up to formulate high-protein diet plans that support muscle maintenance amidst weight loss.

Pharmaceutical giants, including Eli Lilly, are at the forefront of innovation, developing drugs that offer a dual approach to weight loss by facilitating fat reduction while safeguarding or even augmenting muscle mass. Eli Lilly’s collaboration with BioAge Labs on the experimental compound azelaprag exemplifies this cutting-edge research. Azelaprag seeks to mimic the effects of exercise-induced hormones that play a critical role in muscle metabolism, offering hope for a more balanced fat-to-muscle loss ratio in patients taking drugs like Mounjaro and Zepbound.

Further expanding its arsenal, Eli Lilly’s acquisition of Versanis Bio introduces a novel approach to muscle preservation through bimagrumab, a drug that targets receptors involved in muscle and fat regulation. This promising development is backed by research suggesting enhanced muscle growth upon receptor blockade.

Clinical trials are also exploring combinations of existing weight loss drugs with new treatments to address the muscle loss conundrum. One such study involves the pairing of bimagrumab with semaglutide, the active ingredient in Ozempic, to investigate its potential in mitigating frailty in adults with obesity. Additionally, the FDA’s recent approval of a trial for a compound aimed at older adults signifies a proactive approach to preventing muscle deterioration alongside fat loss in this vulnerable demographic.

Despite the promise of these emerging treatments, their availability to the general public is anticipated to be several years away. This delay underscores the importance of immediate, accessible strategies for muscle preservation. Experts highlight the critical nature of maintaining muscle integrity, especially for older adults and postmenopausal women, who face a higher risk of frailty and osteoporosis with muscle loss. The consensus among healthcare providers is that a combination of protein-rich diets and strength training exercises remains a fundamental remedy against muscle depletion.

Capitalising on this need, companies are introducing products and services tailored to individuals on weight loss medications. From protein shakes designed to complement these drugs to specialised fitness programmes and nutritional counselling aimed at enhancing protein intake and mitigating malnutrition risks, the market is rapidly adapting.

Innovative telehealth solutions like Noom’s Muscle Defense programme, which integrates fitness guidance with dietary tracking, and fitness platforms such as Obé Fitness’s MuscleGuard, exemplify the digital response to this challenge. Additionally, initiatives like LifeTime Fitness’s clinic pilot in Minnesota, which combines personalised training with access to compounded weight loss medications, signal a growing trend towards holistic health solutions that encompass both pharmaceutical and lifestyle interventions.

While specialised programmes offer valuable support for muscle preservation, the essence of combating muscle loss lies in fundamental lifestyle adjustments. Incorporating moderate strength training and a balanced, protein-rich diet into one’s routine can be a pragmatic and effective strategy for those navigating the complexities of weight loss medications.

FDA issues alert on counterfeit semaglutide products in the U.S.

The U.S. Food and Drug Administration (FDA) has recently issued a crucial warning to adults with diabetes in the United States about the presence of counterfeit semaglutide in the country’s drug supply chain. This alert comes following an ongoing FDA investigation into the distribution of fake versions of the 1 mg subcutaneous semaglutide, known commercially as Ozempic and manufactured by Novo Nordisk.

The FDA’s investigation has led to the seizure of thousands of units of these counterfeit products. Key identifiers of the fake medication include lot number NAR0074 and serial number 430834149057. These specific batches have been confirmed as counterfeit and are advised not to be used.

A further cause for concern highlighted by the FDA is the discovery of counterfeit needles accompanying the medication. The sterility of these needles cannot be assured, posing a heightened risk of infection for users. Additional counterfeit components identified by the FDA include the pen label, health care professional and patient information leaflets, and the packaging box.

The FDA is urging wholesalers, retail pharmacies, healthcare providers, and patients to diligently check their semaglutide products’ lot and serial numbers. While the FDA, in partnership with Novo Nordisk, is currently conducting tests on the seized counterfeit products, there is yet no comprehensive information about the content, quality, or safety of these fakes.

To date, the FDA has received reports of five adverse events associated with the use of these counterfeit semaglutide products. These incidents align with the typical side effects of authentic semaglutide, and thankfully, none of the reported cases have been serious. The FDA encourages reporting of any adverse events through its MedWatch Safety Information and Adverse Event Reporting Program, either via online submission or fax at (1-800) FDA-0178.

The FDA advises pharmacies to source genuine semaglutide only through Novo Nordisk’s approved distributors. Patients should obtain the drug strictly with a valid prescription from state-licensed pharmacies and are advised to inspect the product thoroughly for any signs of counterfeiting before use. Any suspicions or discoveries of counterfeit products should be promptly reported to the FDA. This can be done by calling the local FDA consumer complaint coordinator or by reporting directly via the FDA’s official website.

Innovative vibrating pill may combat obesity by inducing satiety

Researchers at the Massachusetts Institute of Technology, led by Giovanni Traverso, have developed an innovative approach to tackling obesity using a vibrating pill. This method promises a less invasive alternative to gastric bypass surgery and aims to be more cost-effective and less prone to side effects than current pharmacological treatments like Wegovy and Ozempic.

The pill, approximately the size of a standard multivitamin tablet, contains a vibrating motor powered by a small, ingestible silver oxide battery. Upon reaching the stomach, the pill’s outer layer is dissolved by gastric acid, triggering an electronic circuit that activates the vibration.

In a pivotal experiment involving pigs, it was observed that those administered the pill 20 minutes before mealtime consumed roughly 40% less food than their counterparts who did not receive the pill. Additionally, these pigs exhibited elevated levels of blood hormones typically associated with satiety.

Traverso and his team are optimistic about commencing human trials soon, given the prevalent issue of obesity, which affects over 40% of the population in the United States alone. The pill works by stimulating receptors that sense stomach expansion post a substantial meal, thereby sending fullness signals to the brain.

The current prototype of the pill is designed to vibrate for a duration of 30 minutes before the battery depletes, after which it is naturally excreted from the body. Traverso envisions future iterations of the pill that could remain semi-permanently in the stomach, with the ability to be wirelessly activated or deactivated as needed. This individualised response could lead to daily automatic activation to reduce overall appetite or even manual control via a smartphone app to address specific hunger cues.

This research builds upon previous findings by the same team, which discovered that electrical stimulation of the stomach lining can induce hunger. Such findings open the door to potential treatments for appetite loss in individuals with conditions like cancer. Traverso expresses excitement about the possibilities of manipulating different parts of the gastrointestinal tract to replicate the sensation of fullness, posing the question of whether it is possible to create an illusion of satiety through such stimulation.

Swiss pharmaceutical giant Roche enters obesity drug race with $2.7 billion Carmot deal

Swiss pharmaceutical giant, Roche, has announced a significant strategic move in the obesity treatment market with its $2.7 billion acquisition of Carmot Therapeutics, a U.S.-based obesity drug developer. This places Roche among leading contenders like Novo Nordisk and Eli Lilly in the weight-loss drug sector. Carmot’s flagship product, CT-388, a once-a-week dual GLP-1/GIP receptor agonist injection similar to Lilly’s Mounjaro, has shown promise in Phase I trials and is poised for Phase II testing. Its market introduction is anticipated in the 2030s.

The move has generated optimism, reflected in a 2.4% rise in Roche shares, as the weight-loss drug market, potentially worth $100 billion, appears to have room for multiple players. Roche’s Teresa Graham, head of the pharmaceuticals division, expressed ambitions beyond merely competing on price, envisioning CT-388 as a leading obesity drug in its class.

This acquisition marks Roche’s re-entry into the GLP-1 field, following a previous exit in 2018 when subsidiary Chugai sold experimental drug rights to Lilly. The Carmot deal, expected to conclude in early 2024, includes additional payments of up to $400 million subject to achievement of certain milestones.

The deal is part of Roche’s broader strategy, under new CEO Thomas Schinecker, to diversify its therapeutic fields and rejuvenate its development pipeline, especially after setbacks in Alzheimer’s and cancer immunotherapy. Besides the Carmot acquisition, Roche recently committed $7.1 billion for rights to a new drug for inflammatory bowel disease.

Carmot, founded in 2008, has a portfolio of various gut-hormone drug candidates, in both pill and injectable forms, designed to treat obesity in patients with and without diabetes. This acquisition underlines Roche’s commitment to expanding its presence in the evolving field of obesity treatment.

Novo Nordisk’s $2.3 billion French investment to enhance obesity drug output

Novo Nordisk has declared a substantial $2.3 billion investment aimed at amplifying the output of its highly sought-after obesity and diabetes medications at its Chartres facility in France, in a move to satiate the escalating demand. This financial injection will notably enhance the manufacturing capabilities for existing products such as Ozempic and Wegovy, alongside other burgeoning obesity treatments, according to the Danish pharmaceutical giant.

Europe is currently grappling with a supply crisis of the diabetes medication Ozempic, which shares the active ingredient semaglutide with the widely acclaimed weight management drug Wegovy—yet to be broadly distributed across Europe.

In response to the off-label consumption of Ozempic, Novo Nordisk has imposed restrictions within the European Union. Concurrently, Germany is considering export prohibitions, while Belgium has already enacted a ban on prescribing the weekly injection for non-diabetes purposes.

Despite efforts by the UK government to restrict the use of Ozempic to non-weight loss purposes in July, a Reuters investigation discovered the drug is still being acquired by individuals without diabetes for weight management.

This announcement follows Novo Nordisk’s recent proclamation of a $6 billion expenditure in Denmark to augment production capabilities. Additionally, this venture represents a significant endorsement for French President Emmanuel Macron’s economic strategies amidst a looming global downturn, aiming to sustain the momentum in reducing French unemployment figures.

President Macron had advocated for this investment during his “Choose France” summit, which reportedly persuaded Novo Nordisk’s CEO Lars Fruergaard Jorgensen to commit to the expansion. The investment also echoes Eli Lilly’s recent decision to construct a $2.5 billion manufacturing plant in Germany, similarly motivated by heightened demand for diabetes and obesity treatments.

Analysts predict the obesity drug market could reach a staggering $100 billion by 2030. Novo Nordisk’s French investment will notably expand its capacity for intricate manufacturing processes, specifically the intricate filling of injection pens with semaglutide, and the subsequent assembly and packaging of these pens.

Though details were scant earlier this month regarding the augmentation of in-house production for Ozempic and Wegovy’s European variant, Novo Nordisk has confirmed that the Chartres expansion has commenced, with completion slated between 2026 and 2028, promising the creation of 500 new job opportunities, adding to the near 2,000-strong workforce currently employed at the factory.

Eli Lilly announces multibillion-euro German plant to scale up obesity drug production

Eli Lilly and Company, the American pharmaceutical giant, has announced plans to establish its first production facility in Germany, situated in the western town of Alzey, with an investment of 2.3 billion euros ($2.5 billion). This move, initially reported by Reuters, comes in response to the rapidly escalating demand for innovative diabetes and obesity treatments. The strategic investment will expand the production capabilities for key diabetes and obesity medications, including Mounjaro and Trulicity, as well as the injection devices required for their administration.

On Friday, Eli Lilly highlighted the significant role Germany’s skilled workforce will play in enhancing the company’s supply of incretin-based treatments, with the site expected to become operational in 2027. Incretins, a class of peptide-based medications like Mounjaro, are designed to mimic intestinal hormones that curb appetite and promote insulin release.

The expansion of Eli Lilly’s manufacturing footprint into Germany aligns with broader industry trends, where pharmaceutical companies are facing mounting political pressure to localise the production of critical healthcare products. The COVID-19 pandemic brought to light the fragility of global supply chains, prompting a reevaluation of manufacturing strategies to better serve market demands.

The German Health Minister, Karl Lauterbach, expressed his support for the investment at a press briefing in Berlin. He underscored the importance of this development for Germany’s stature as a pharmaceutical hub, emphasising the potential for more rapid access to novel treatments and reduced reliance on precarious supply chains.

The selection of Alzey as the site for this new production complex was influenced by several factors, including the availability of a skilled workforce, the existing infrastructure, and the prospect of creating a manufacturing nexus in conjunction with Eli Lilly’s existing site in Fegersheim, France. Edgardo Hernandez, the head of manufacturing at Eli Lilly, pointed out Germany’s rich heritage in engineering and science, as well as the proximity to numerous equipment manufacturers, as pivotal in the site selection process.

Mounjaro is on the cusp of gaining approval for weight loss treatment in the European Union, following the EU drugs regulator’s recommendation for its approval. However, Germany’s public health insurance currently does not cover weight-loss medications, meaning that patients seeking Mounjaro for non-diabetic weight loss will likely have to bear the costs independently. Minister Lauterbach indicated that there are no immediate plans to reassess these regulations.

Over the past three years, Eli Lilly has made public commitments exceeding $11 billion towards global manufacturing. In their third-quarter financial disclosure, the company earmarked over $8 billion for expansion projects in Indiana, North Carolina, and Limerick, Ireland, over the coming years. Despite this, Eli Lilly anticipates continued supply constraints while it ramps up manufacturing capacity. Concurrently, the firm has appealed to medical professionals outside the United States to halt new patient prescriptions of Trulicity due to heightened demand.

This investment announcement occurs amidst vigorous debate over the European Union’s proposal to reduce the standard period for market exclusivity, prompting Eli Lilly to invest strategically in the region and partake in shaping industry dialogue.

Eli Lilly, with a longstanding presence in Germany since 1960 and a current workforce of 1,000 employees in various domains, anticipates the new Alzey facility will create up to 1,000 high-calibre jobs for engineers, technicians, and scientists, further reinforcing the company’s commitment to innovation and healthcare advancement.

The limited impact of Ozempic on the U.S. obesity epidemic

The term ‘obesity’ elicits a range of interpretations. Some view it as merely another way to describe excess weight, while others perceive it as a derogatory label for larger body sizes. Still, some consider it a reflection of personal failings, such as a lack of discipline or willpower. However, for over a decade, the medical field has acknowledged obesity as a chronic health condition, akin to diseases like cancer, diabetes, and hypertension. This disease significantly elevates the risk of severe COVID-19 outcomes, is connected to numerous health complications, and is responsible for approximately 4 million preventable deaths annually. Moreover, obesity manifests in various forms, with diverse origins, clinical signs, and treatment responses.

The surge in popularity of GLP-1 medications such as Ozempic, Wegovy, and Mounjaro has somewhat simplified this complex issue. These drugs are often hailed as the ultimate solution to obesity, a perspective that overlooks the multifaceted nature of the condition. Unfortunately, Ozempic alone cannot address America’s obesity crisis. Obesity extends beyond mere physical inactivity or excessive eating. It’s influenced by a range of factors including genetic predispositions, mental health, socio-economic conditions, and environmental factors.

In clinical settings, the variation in obesity cases is significant. For instance, a mutation in the MC4R gene is associated with an 18% increased likelihood of obesity, while certain antipsychotic medications can lead to substantial weight gain. Although GLP-1 medications can be beneficial, they primarily address hormonal imbalances and do not tackle other contributing factors. This reductionist approach is also evident in the use of Body Mass Index (BMI) to diagnose obesity. BMI, initially designed for white European males, often inaccurately represents obesity levels in different ethnic groups, leading the American Medical Association to advise against its sole use. Currently, a global commission of experts is redefining obesity, moving away from height and weight measurements to focus on specific symptoms and signs.

The response to treatment among patients with obesity also varies greatly. For example, the GLP-1 drug Wegovy showed an average body weight reduction of 16% in a study, yet individual results ranged widely. This underscores the need for personalised treatment plans rather than a singular drug-based approach. However, the U.S. healthcare system faces significant challenges in this regard. With only a small number of physicians specialised in obesity treatment and federal restrictions on covering obesity medications, only a fraction of those who could benefit from such treatments receive them. Instead, many are advised to simply eat less and exercise more, a strategy that overlooks the complexity of obesity.

Effective obesity treatment involves a multidisciplinary approach, combining diet, exercise, behavioural therapy, medication, and sometimes surgery. Unfortunately, the scarcity of specialised physicians and the prevalence of misleading diet products and scams exacerbate the issue. The U.S. weight loss market, valued at $160 billion in 2023, is a testament to this. Moreover, misconceptions about GLP-1 medications, such as the idea that they are a cure-all for obesity, lead to unrealistic expectations and criticisms. Like insulin or hypertension treatments, discontinuing GLP-1 drugs can result in a reversal of their effects, a fact that should be recognised rather than criticised.

Addressing obesity, which costs the U.S. around $1.7 trillion annually, requires acknowledging the progress made with GLP-1 drugs while also understanding their limitations. A holistic, patient-centred, and empathetic approach to obesity treatment is essential. This approach should not only address the unique needs and circumstances of each individual but also aim to improve overall health and well-being. While medications like Ozempic, Wegovy, and Mounjaro offer significant potential, they are not the all-encompassing solution often portrayed in the media. A broader, more nuanced understanding and response to obesity is crucial for effective management and treatment.

AstraZeneca makes big push into obesity treatment with new pill partnership

AstraZeneca, the United Kingdom’s pharmaceutical giant, has entered a strategic partnership with Eccogene, a Shanghai-based biotech firm, to co-develop a groundbreaking pill designed to combat obesity and type 2 diabetes.

This alliance marks AstraZeneca’s significant foray into the burgeoning sector of weight management medications, underpinned by an exclusive licensing contract focusing on an investigational drug, ECC5004. The said compound is touted to address not only obesity but also a spectrum of cardiometabolic disorders, including heart disease and stroke, ailments afflicting over a billion people worldwide.

Eccogene is poised to receive payments that could sum up to a substantial $2 billion, which is approximately £1.6 billion, as per the agreed terms.

ECC5004 is currently undergoing phase 1 trials, with AstraZeneca setting its sights on advancing to phase 2 clinical evaluations by the subsequent year’s end. Additionally, the pharma titan is nurturing two other nascent-stage injectable obesity therapies.

The innovative ECC5004, if it passes clinical muster, is envisioned to be administered orally once daily, a standalone treatment or potentially in conjunction with other drugs targeting various cardiometabolic diseases. This positions it distinctively against the prevailing injectables that are typically administered weekly.

Operating as a GLP-1 agonist, ECC5004 is designed to replicate the function of the GLP-1 hormone, which is naturally secreted post-food intake.

Pascal Soriot, AstraZeneca’s CEO, highlighted the critical demand for effective obesity interventions across Western nations, Latin America, and South Asia, where abdominal obesity is rampant, precipitating heightened risks of hypertension and diabetes.

Soriot indicated that while the journey to market might span several years, ECC5004 could potentially be more economically accessible than existing options. Due to its simplified chemical structure that permits cheaper production costs, the drug could cater to a wider demographic, including those in lower-income nations where AstraZeneca maintains a robust footprint.

As the competition intensifies in the international market for obesity drugs, demand has surged for Novo Nordisk’s Wegovy and Ozempic, prompting supply challenges. With Wegovy’s pricing set at £73.25 per pack monthly on the NHS and reaching £199 at retail pharmacies, its sales and profits have climbed sharply, elevating Novo Nordisk to be Europe’s highest-valued company by market capitalisation.

Notably, Eli Lilly’s Mounjaro has demonstrated superior weight loss outcomes compared to Wegovy and recently secured approvals for weight management in the UK and US. Market analysts from UBS have predicted that Mounjaro could emerge as one of the most successful pharmaceuticals ever, with projected peak sales around £20 billion.

Pharmaceutical titans Novo Nordisk, Eli Lilly, and Pfizer are all in the race to create oral anti-obesity medications, which promise cost-effectiveness and ease of administration over injections.

Bolstered by its oncology drugs and the diabetes treatment Forxiga, AstraZeneca has reported a 5% revenue increase, totaling $33.8 billion in the year’s first three quarters. The firm also lifted its revenue and profit forecasts for the full year, announcing approvals for additional cancer treatments.

AstraZeneca’s COVID-19 vaccine, crafted in collaboration with Oxford University, was pivotal during the pandemic, credited with saving over 6 million lives globally within its inaugural year as per independent assessments.

However, AstraZeneca currently faces two high court cases in London related to the vaccine’s side effects. The company is expected to contest these allegations.

The World Health Organization last year affirmed the vaccine’s safety and efficacy for individuals 18 years and older, labelling TTS occurrences as exceptionally rare and characteristically presenting severe blood clots.